Drug Profile
Research programme: peptidoglycan hydrolase fusion proteins - AdRem Biotech
Alternative Names: 1401; ABI-200Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AdRem Biotech
- Class Bacteriocins; Endolysins; Recombinant proteins
- Mechanism of Action Cell wall inhibitors; Hydrolase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gram-positive-infections in USA (Topical)
- 06 Oct 2009 Preclinical trials in Gram-positive infections in USA (Topical)